AXSM (MC $85 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017 = 2000%+ POTENTIAL..UNKNOWN LOW FLOAT GEM !!!
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $85 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $85 Million Cash: $50.6 Million(cash runway into the first quarter of 2019.) Price:$3.70
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.)
AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.)
AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.)
AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.)
AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
Here's a cut/paste fron yesterdays SEC filing. Choke on this shareholders. They've been fleecing generations of fools and enriching themselves in the process. Summary Compensation Table The following table sets forth certain summary information for the years indicated concerning the compensation earned by the Company’s current and former Chief Executive Officer, Chief Financial Officer, and two individuals who would have been one of our three most highly compensated executive officers except for the fact that they were not serving as executive officers as of December 31, 2016.
Name and Principal Position
Year Salary ($) Stock Awards ($)(1) Option Awards ($)(2) Non-Equity Incentive Plan Compensation ($)(3) All other Compensation ($)(4) Total ($) James Neal
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0 In other words, the correlation coefficient of the other stocks
Received an alert this am about $XOMA from http://yugestocks.com/?s=XOMA, you may want to take a look. Terman's law: there is no direct relationship between the quality of an educational program and its cost. Trading stocks making money.
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
My whopping 100 shares are going up. Thanks for the R/S COMA
Perhaps a short-term pull back is more likely before the next rally on XOMA? Not sure how aawesomestocks finds all these incredible trade ideas but im happy.
I new I should have waited a bit longer...the news is just the beginning for XOMA.
Looking for a good entry again.
I have no faith or trust in XOMA, they have stuck it to the investors to many times and a reverse split like the last was uncalled for. I will guess that the pump of lately is false just like always.
Looks like they have $ for the time being. Is there a FDA announcement ready to hit the wires ?
Is the World coming to an end? Why is XOMA moving up? Just because they paid off some of their debts?
I ask every investor in xoma to check out http://www.cnbc.com/pre-markets/, select xoma under " search quotes....". You'll find a slide presented this morning. Shows the HUGE potential for their products in the pipeline ( $$ ). The new guy in the B.of D. brought in $25 mill. He'll speed up the sale of the company to be able to recover ( and make some ) of his investment. After all, things look good to me. All we need is some patience and accumulate when others are scared.
Announcing the cc only 2 days in advance points to some BIG news ( " ...XOMA’s new strategic direction and initiatives " ).. This is right after a prominent VC person joins the board. Guess there is a 80-90% chance the company will be sold or a major strategic partner was found. We'll see.